Effectiveness and safety of opicapone in Parkinson's disease patients with motor fluctuations: the OPTIPARK open-label study

Translational Neurodegeneration
Heinz ReichmannOPTIPARK investigators

Abstract

The efficacy and safety of opicapone, a once-daily catechol-O-methyltransferase inhibitor, have been established in two large randomized, placebo-controlled, multinational pivotal trials. Still, clinical evidence from routine practice is needed to complement the data from the pivotal trials. OPTIPARK (NCT02847442) was a prospective, open-label, single-arm trial conducted in Germany and the UK under clinical practice conditions. Patients with Parkinson's disease and motor fluctuations were treated with opicapone 50 mg for 3 (Germany) or 6 (UK) months in addition to their current levodopa and other antiparkinsonian treatments. The primary endpoint was the Clinician's Global Impression of Change (CGI-C) after 3 months. Secondary assessments included Patient Global Impressions of Change (PGI-C), the Unified Parkinson's Disease Rating Scale (UPDRS), Parkinson's Disease Questionnaire (PDQ-8), and the Non-Motor Symptoms Scale (NMSS). Safety assessments included evaluation of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). Of the 506 patients enrolled, 495 (97.8%) took at least one dose of opicapone. Of these, 393 (79.4%) patients completed 3 months of treatment. Overall, 71.3 and 76.9% of patients experien...Continue Reading

References

Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Feb 13, 2003·Archives of Neurology·Claudia J ChavesSteven Warach
Feb 27, 2003·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J P LarsenUNKNOWN NOMESAFE Study Group
Sep 24, 2004·Movement Disorders : Official Journal of the Movement Disorder Society·Stéphane ChapuisFranck Durif
Jul 1, 2005·Current Neurology and Neuroscience Reports·K Ray ChaudhuriP Martinez-Martin
Nov 11, 2006·Clinical Neuropharmacology·Mark StacyEduardo Tolosa
Aug 4, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Kallol Ray ChaudhuriAnthony H V Schapira
Oct 9, 2007·Parkinsonism & Related Disorders·Peter RiedererHeinz Reichmann
Apr 21, 2009·Lancet Neurology·K Ray Chaudhuri, Anthony H V Schapira
Jun 1, 2007·Journal of Clinical Neurology·Tae-Beom AhnBeom S Jeon
Jan 13, 2010·Archives of Neurology·Lisa M ShulmanWilliam J Weiner
Mar 25, 2010·European Neurology·Fabrizio StocchiJose A Obeso
Mar 26, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserUNKNOWN Parkinson Study Group
Nov 11, 2011·CNS Neuroscience & Therapeutics·Spyridon Spyros Papapetropoulos
Jan 3, 2013·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraW H Oertel
May 1, 2013·Movement Disorders : Official Journal of the Movement Disorder Society·C Warren OlanowUNKNOWN Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators
Jun 14, 2014·European Journal of Clinical Pharmacology·José-Francisco RochaPatrício Soares-da-Silva
Jun 24, 2014·Parkinsonism & Related Disorders·Marlene C HechtnerRafael Mikolajczyk
Jul 19, 2014·Brain : a Journal of Neurology·Roberto CiliaGianni Pezzoli
Aug 1, 2014·Journal of Medicinal Chemistry·László E Kiss, Patrício Soares-da-Silva
Aug 3, 2017·The New England Journal of Medicine·Thomas R Frieden
Aug 15, 2017·International Review of Neurobiology·Christiana Franke, Alexander Storch
Mar 24, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Susan H FoxUNKNOWN Movement Disorder Society Evidence-Based Medicine Committee
Sep 29, 2018·Movement Disorders : Official Journal of the Movement Disorder Society·Margherita FabbriOlivier Rascol
Jan 27, 2019·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·J J FerreiraP Soares-da-Silva
Apr 11, 2019·Clinical Pharmacology and Therapeutics·Alison CavePeter Arlett

❮ Previous
Next ❯

Citations

Nov 26, 2020·The Annals of Pharmacotherapy·Erin St OngeShannon Miller
Oct 27, 2020·Journal of Parkinson's Disease·Giovanni AbbruzzeseUNKNOWN SYNAPSES Study Investigators Group

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02847442

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.